Online inquiry

IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8654MR)

This product GTTS-WQ8654MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM), AL amyloidosis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8654MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2221MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA aVWF81
GTTS-WQ14127MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA aPCSK927
GTTS-WQ1387MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABT-981
GTTS-WQ15377MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TRU-016
GTTS-WQ15997MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ZW-25
GTTS-WQ6678MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ6368MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ3622MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY 1179470
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW